We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
301
DELISTED
Repare Therapeutics
RPTX
$213K 0.09%
6,828
-784
-10% -$25.7K
MRTX
302
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$213K 0.09%
1,318
+40
+3% +$6.42K
ADAP
303
DELISTED
Adaptimmune Therapeutics
ADAP
$212K 0.09%
49,819
-23,418
-32% -$114K
BOLT icon
304
Bolt Biotherapeutics
BOLT
$7.8M
$212K 0.09%
+685
New +$278K
ZNTL icon
305
Zentalis Pharmaceuticals
ZNTL
$318M
$212K 0.09%
3,992
-1,827
-31% -$97.8K
CMRX
306
DELISTED
Chimerix, Inc.
CMRX
$212K 0.09%
+26,472
New +$220K
ARCT icon
307
Arcturus Therapeutics
ARCT
$163M
$211K 0.09%
6,229
+3,444
+124% +$117K
RYTM icon
308
Rhythm Pharmaceuticals
RYTM
$7.38B
$211K 0.09%
10,765
+826
+8% +$17.2K
ALLK
309
DELISTED
Allakos
ALLK
$210K 0.09%
2,462
-18
-0.7% -$1.8K
ARQT icon
310
Arcutis Biotherapeutics
ARQT
$3.51B
$210K 0.09%
7,692
-2,610
-25% -$73.5K
ARWR icon
311
Arrowhead Research
ARWR
$12.1B
$210K 0.09%
2,530
-1,476
-37% -$110K
RCKT icon
312
Rocket Pharmaceuticals
RCKT
$359M
$210K 0.09%
4,734
-627
-12% -$27.2K
PRVB
313
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$210K 0.09%
24,909
+8,751
+54% +$70.6K
KDMN
314
DELISTED
Kadmon Holdings, Inc.
KDMN
$210K 0.09%
54,162
-13,619
-20% -$52.8K
ITOS
315
DELISTED
iTeos Therapeutics
ITOS
$209K 0.09%
8,134
-1,958
-19% -$46.7K
OLMA icon
316
Olema Pharmaceuticals
OLMA
$1.09B
$209K 0.09%
+7,479
New +$213K
AMTI
317
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$209K 0.09%
4,565
-4,859
-52% -$230K
MRUS
318
DELISTED
Merus
MRUS
$208K 0.09%
+9,876
New +$218K
TECX
319
Tectonic Therapeutic
TECX
$579M
$208K 0.09%
1,950
+96
+5% +$11.4K
HYD icon
320
VanEck High Yield Muni ETF
HYD
$4.45B
$207K 0.09%
+3,250
New +$204K
PGEN icon
321
Precigen
PGEN
$1.98B
$207K 0.09%
31,729
-798
-2% -$5.58K
SPRY icon
322
ARS Pharmaceuticals
SPRY
$562M
$207K 0.09%
+6,701
New +$215K
XNCR icon
323
Xencor
XNCR
$1.48B
$207K 0.09%
5,992
-551
-8% -$21.8K
SYRS
324
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$207K 0.09%
3,798
+1,221
+47% +$72.3K
ALDX icon
325
Aldeyra Therapeutics
ALDX
$93.5M
$206K 0.08%
+18,201
New +$219K
11 12
13
14 15

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.